This deal adds two more siRNA candidates to GSK’s pipeline, which the company is looking to expand as it looks to offset the ...

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from China’s Frontier Biotechnologies. | GSK is continuing to bolster its siRNA ...

GSK (GSK) stock is in focus as the company inks a drug licensing deal worth up to $1B with China's Frontier Biotechnologies for siRNA treatments. Read more here.

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own ...

(Yicai) Feb. 24 -- Shares of Frontier Biotechnologies surged after the Chinese drugmaker granted UK pharmaceutical giant GSK the exclusive global rights to two small nucleic acid therapies it is ...

Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple ...

Madrigal is eying an expansion of MASH blockbuster Rezdiffra’s capabilities via combination with precision siRNA gene ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

Researchers develop a 3D-printed, RNA-activated implant that silences the PTEN gene to promote nerve regrowth after spinal ...